Chlorthalidone vs Hydrochlorothiazide for Hypertension-CV Events: Did the Design Influence the Outcome?

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Elderly hypertensive patients often use Hydrochlorothiazide (HCTZ).
• Chlorthalidone (CTD) is an alternative diuretic for hypertension management.
• Real-world studies offer pragmatic insights but have design limitations.

Purpose of the Study:

• To pragmatically evaluate if Chlorthalidone (CTD) reduces cardiovascular disease (CVD) risk versus Hydrochlorothiazide (HCTZ).
• To assess outcomes in elderly hypertensive patients (≥65 years) on baseline HCTZ therapy.

Main Methods:

• A real-world study comparing CTD and HCTZ in elderly hypertensive patients.
• Participants were on 25 or 50 mg HCTZ at baseline.
• Analysis considered patient risk stratification (history of MI/Stroke).

Main Results:

• In high-risk patients (history of MI/Stroke), CTD showed a lower risk of the primary CVD outcome compared to HCTZ.
• No significant difference in outcomes was observed between CTD and HCTZ in low-risk populations.
• Study limitations included unequal diuretic exposure and lack of established dose equivalency.

Conclusions:

• CTD may offer a cardiovascular benefit over HCTZ in high-risk elderly hypertensive individuals.
• Real-world study design limitations, such as unequal exposure, may influence observed outcomes.
• Further research with robust trial designs is needed to confirm diuretic efficacy in hypertension.